Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-02-2023 | Pleural Mesothelioma | Case report

Gemcitabine/pembrolizumab/pemetrexed

Fatigue following drug toxicity and lack of efficacy: case report

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Metaxas I, et al. Radip response to chekpoint inhibition therapy in a patient with malignant peritoneal mesothelioma. Oncology Research and Treatment 42 (Suppl. 4): 116-117, Oct 2019. Available from: URL: http://doi.org/10.1159/000502425 [abstract] Metaxas I, et al. Radip response to chekpoint inhibition therapy in a patient with malignant peritoneal mesothelioma. Oncology Research and Treatment 42 (Suppl. 4): 116-117, Oct 2019. Available from: URL: http://​doi.​org/​10.​1159/​000502425 [abstract]
Metadata
Title
Gemcitabine/pembrolizumab/pemetrexed
Fatigue following drug toxicity and lack of efficacy: case report
Publication date
01-02-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-33216-z

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Insulin

Case report

Paracetamol

Case report

Multiple drugs